NCT01064453View on ClinicalTrials.gov

Angeliq Regulatory Post Marketing Surveillance

CompletedOBSERVATIONAL

Enrollment

4,078

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Postmenopausal PeriodOsteoporosis, Postmenopausal

Interventions

DRUG

E2/DRSP (Angeliq, BAY86-4891)

Take one tablet daily, continuously

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY